COMPANY PROFILE

Uvax Bio

Explore full profile

Innovative vaccine solutions leveraging proprietary 1c SA p platform technology for HIV and other infectious diseases

Newark, United StatesFounded 2018Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Uvax Bio

Uvax Bio is a clinical-stage vaccine company specializing in the development of innovative vaccines using its proprietary 1c SA p platform technology. Founded in 2018 by Dr. Jiang Zhu, the company focuses on creating vaccines for infectious diseases, with a current emphasis on HIV. Uvax Bio operates in the biotechnology sector, targeting both public health organizations and private healthcare providers as its primary clients. The company’s business model revolves around research and development, followed by clinical trials, and eventual commercialization of its vaccine candidates. Revenue is generated through grants, sponsorships, and potential future sales of approved vaccines. Recently, the National Institutes of Health (NIH) agreed to sponsor a Phase 1 clinical trial for Uvax Bio's HIV vaccine candidates, marking a significant milestone. The company is also preparing three new vaccine assets for further development.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Newark, United States
Employees: 6
Open positions: None listed
Dealroom signal: 57.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Vaccines, Antibodies, Spinout, Biotech and Pharma, DT and LS, science-based
Technology: Deep Tech, Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Uvax Bio.

See all news

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Apr 2025	$2.6M	—	Coalition for Epidemic Preparedness	↗
EARLY VCOther financing	Sep 2020	$11M	$44M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Uvax Bio website traffic

Latest recorded traffic for Uvax Bio is 1.8K monthly website visits, up 260% over the last three months. Uvax Bio's team declined 33.3% over the past year.

Latest monthly visits1.8K 3-month web change+260% 1-year team growth-33.3%

Monthly website visitsNov 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IMImmuneedDeveloping a new generation of prostate cancer vaccines, based on activation of the body's own immune system	Uppsala kommun, Sweden	Acquired	16	$520K	$2.1M
IMIMMUNETHEPBiotech start-up company that is developing broad coverage anti-bacterial immunotherapies	Cantanhede, Portugal	Operational
MAManaAn AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy	Tel Aviv-Yafo, Israel	Operational
APAbolerIS PharmaNovel monoclonal antibody inducing durable autoimmune remission	Charleroi, Belgium	Operational
PTpHion TherapeuticsDeveloping Next Generation mRNA Vaccines	Belfast, United Kingdom	Operational
EBEvaxion BiotechPioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence	Hørsholm, Denmark	Operational
BBBarinthus BiotherapeuticsT cell immunotherapeutics for chronic infectious diseases	Harwell, United Kingdom	Acquired
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational